These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 34298798)

  • 1. DNA Methylation and Intra-Clonal Heterogeneity: The Chronic Myeloid Leukemia Model.
    Lebecque B; Bourgne C; Vidal V; Berger MG
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34
    Maupetit-Mehouas S; Court F; Bourgne C; Guerci-Bresler A; Cony-Makhoul P; Johnson H; Etienne G; Rousselot P; Guyotat D; Janel A; Hermet E; Saugues S; Berger J; Arnaud P; Berger MG
    Mol Oncol; 2018 Jun; 12(6):814-829. PubMed ID: 29575763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of Chronic Myeloid Leukaemia (CML) as a Disease Model to Define and Study Clonal Heterogeneity.
    Berger MG; Bourgne C
    Adv Exp Med Biol; 2019; 1139():171-185. PubMed ID: 31134501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options.
    Koschmieder S; Vetrie D
    Semin Cancer Biol; 2018 Aug; 51():180-197. PubMed ID: 28778403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia.
    Zhou JD; Lin J; Zhang TJ; Ma JC; Li XX; Wen XM; Guo H; Xu ZJ; Deng ZQ; Zhang W; Qian J
    J Cell Physiol; 2018 Mar; 233(3):2444-2450. PubMed ID: 28776669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
    Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
    Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current perspectives for the treatment of chronic myeloid leukemia.
    Aladağ E; Haznedaroğlu İC
    Turk J Med Sci; 2019 Feb; 49(1):1-10. PubMed ID: 30761815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function?
    Vatanmakanian M; Tavallaie M; Ghadami S
    Cell Commun Signal; 2019 Apr; 17(1):38. PubMed ID: 31014357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia.
    Asimakopoulos FA; Shteper PJ; Krichevsky S; Fibach E; Polliack A; Rachmilewitz E; Ben-Neriah Y; Ben-Yehuda D
    Blood; 1999 Oct; 94(7):2452-60. PubMed ID: 10498618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical implications of clonal chromosomal abnormalities in Philadelphia negative cells in CML patients after treated with tyrosine kinase inhibitors.
    Ni H; Sun X; Xu Y; Lyle D; Petersen P; Zhao X; Drum H; You B; Liu D; Liu C; Jiang JG
    Cancer Genet; 2019 Oct; 238():44-49. PubMed ID: 31425925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
    Akram AM; Iqbal Z; Akhtar T; Khalid AM; Sabar MF; Qazi MH; Aziz Z; Sajid N; Aleem A; Rasool M; Asif M; Aloraibi S; Aljamaan K; Iqbal M
    Cancer Biol Ther; 2017 Apr; 18(4):214-221. PubMed ID: 28278078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactive oxygen species in BCR-ABL1-expressing cells - relevance to chronic myeloid leukemia.
    Antoszewska-Smith J; Pawlowska E; Blasiak J
    Acta Biochim Pol; 2017; 64(1):1-10. PubMed ID: 27904889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.
    Jin B; Wang C; Shen Y; Pan J
    Cell Death Dis; 2018 Jan; 9(2):68. PubMed ID: 29358661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
    Wöhrle FU; Halbach S; Aumann K; Schwemmers S; Braun S; Auberger P; Schramek D; Penninger JM; Laßmann S; Werner M; Waller CF; Pahl HL; Zeiser R; Daly RJ; Brummer T
    Leukemia; 2013 Jan; 27(1):118-29. PubMed ID: 22858987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
    An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
    Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.
    Etienne G; Dulucq S; Huguet F; Schmitt A; Lascaux A; Hayette S; Fort MP; Sujobert P; Bijou F; Morisset S; Tavitian S; Bidet A; Turcq B; Robbesyn F; Chollet C; Belloc F; Durrieu F; Mahon FX; Nicolini FE
    Cancer Med; 2019 Sep; 8(11):5173-5182. PubMed ID: 31350815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The roles of DNA epigenetics and clinical significance in Chronic Myeloid Leukemia: a review.
    Keramatinia A; Ahadi A; Akbari ME; Mohseny M; Mosavi Jarahi A; Bahadori-Monfared A; Hashemi M; Moradi A; Mehrvar N; Kazemi E; Movafagh A
    Cell Mol Biol (Noisy-le-grand); 2018 Jun; 64(9):58-63. PubMed ID: 30030958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia.
    Lee H; Basso IN; Kim DDH
    Int J Hematol; 2021 May; 113(5):632-641. PubMed ID: 33772728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
    Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J
    J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of array comparative genomic hybridization in chronic myeloid leukemia.
    Park S; Koh Y; Jung SH; Chung YJ
    Methods Mol Biol; 2013; 973():55-68. PubMed ID: 23412783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.